NCT06614621View on ClinicalTrials.gov

A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
DRUG

Adebrelimab +Etoposide+Platinum-based drugs

Adebrelimab：20mg/kg或1200mg ivgtt ，d1 ，Q3W Etoposide injection (E): 100mg/m2, ivgtt, d1,d2,d3,Q3W Platinum-based drugs：75mg/m2， ivgtt， d1,d2,d3,Q3W

DRUG

Maintenance treatment period:

Adebrelimab：20mg/kg或1200mg，IV, Q3W； Apatinib Mesylate Tablets：250mg，P.O，qod

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV